URGN UroGen Pharma Ltd. Quarterly Revenue Growth

Official company branding of urogen.com (URGN)

Innovative hydrogels for urinary tract therapy are aggressively capturing the market, replacing radical surgery. This quarterly sales growth chart demonstrates the demand for these solutions, where the value of 224.70 reflects this status. UroGen Pharma Ltd. (URGN) bases its drug development on collaboration with oncology centers and urological networks. The operating model relies on full production outsourcing through contract partners adhering to strict international regulations.

URGN (UroGen) Quarterly Revenue Growth Rate history from 07/04/2022 to 11/20/2026

Analytical breakdowns for UroGen Pharma Ltd (URGN)

- current quotes and average value forecast:
- cash balance and cash flow data:
Summary company analysis:UroGen Pharma Ltd. (URGN)
Flagship merchandise of UroGen Pharma

Leveraging its proprietary RTGel technology and FDA approval, UroGen Pharma Ltd. (URGN) is establishing strong market defensibility that must be validated by actual capital inflows. This indicator measures the percentage change in quarterly trading turnover compared to the previous quarter, allowing for an assessment of the business's operational resilience and sales scaling rates. Analyzing quarterly sales dynamics helps investors avoid overpaying for the asset by timely identifying revenue overheating or stagnation.

Competing companies

BeiGene Oncology - Quarterly Revenue Growth|HALO: Revenue Growth QoQ|Revolution Medicines Corp (RVMD) - Revenue Growth QoQ|Quarterly Revenue Growth Rate Ascentage Pharma Group International (AAPG)|Revenue Growth QoQ CG Oncology, Inc.|BCAX: Quarterly Revenue Increase|Revenue Growth QoQ Personalis (PSNL)|Quarterly Revenue Growth Erasca (ERAS)|Quarterly Revenue Growth DCTH (Delcath Systems)|Quarterly Revenue Increase YMAB|AURA - Revenue Growth QoQ|candeltx.com - Sales Change QoQ|ARAY: Quarterly Revenue Growth|Revenue Dynamics QoQ SLS (SELLAS Life Sciences Group, Inc.)|ACTU (Actuate Therapeutics) - Quarterly Revenue Growth|Quarterly Sales Growth Citius Oncology Inc. (CTOR)|Revenue Growth QoQ TuHURA (HURA)|TARA - Quarterly Revenue Growth Rate|Quarterly Revenue Growth FATE (Fate Therapeutics Inc)|Aadi Bioscience Inc (WHWK) - Quarterly Revenue Growth Rate|TScan - Quarterly Revenue Growth|Champions Oncology, Inc. (CSBR) - Quarterly Sales Growth|XBIT (XBiotech Inc.) - Quarterly Sales Growth|CEL-SCI Corporation (CVM) - Quarterly Revenue Growth|Revenue Growth QoQ OS Therapies|RADX: Quarterly Revenue Increase|Revenue Growth QoQ artivabio.com (ARTV)|Quarterly Sales Growth Rate Adlai Nortye|Quarterly Revenue Growth VERU (Veru Corporation)|Sales Change QoQ TPST (Tempest Tx)|XLO: Quarterly Sales Growth|renovarobio.com (RENB) - Quarterly Sales Growth|Mural Bio (MURA) - Revenue Growth QoQ|Kairos Pharma Inc (KAPA) - Quarterly Revenue Growth|Quarterly Sales Growth OKUR|CytoMed Therapeutics (GDTC) - Quarterly Sales Growth Rate|Quarterly Sales Growth CRIS (Curis Inc.)|Quarterly Revenue Growth Apollomics Inc. (APLM)|Revenue Growth QoQ Tharimmune Corp THAR|Advanced Biomed Corp - Revenue Growth QoQ|GNPX: Quarterly Sales Growth|Calidi Biotherapeutics, Inc. (CLDI) - Quarterly Sales Growth|SBFM: Quarterly Revenue Growth|Quarterly Sales Growth Xenetic Biosciences Inc.|Revenue Growth QoQ Salarius Pharmaceuticals Inc|PPBT: Quarterly Revenue Increase|Quarterly Revenue Growth AONC|BGNE (BeOne Medicines) - Quarterly Revenue Increase|Checkpoint Therapeutics, Inc - Quarterly Sales Growth|elevationoncology.com (ELEV) - Quarterly Revenue Growth Rate|iCAD Inc. - Quarterly Revenue Growth|Quarterly Revenue Growth Rate Ikena Oncology|NTBL: Quarterly Revenue Growth|Quarterly Revenue Growth Rate Viracta (VIRX)|MOR (MorphoSys AG) - Quarterly Revenue Growth|NAYA: Quarterly Revenue Increase|Revenue Growth QoQ Ascentage Pharma Group Ltd (AAPGV)